TrianglePalbociclib (NCT02896335)
Palbociclib trial for Metastatic Malignant Neoplasm to Brain (NCT02896335). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with progressive brain metastases. One cohort accepts solid tumors with CDK-pathway alterations; another accepts breast cancer or melanoma. Previous CDK4/6 inhibitors exclude participation; the combination excludes PD1 or PDL1 inhibitors.
The idea: palbociclib blocks cell-growth signaling. Both take it orally for twenty-one days per four-week cycle. The second adds pembrolizumab infusions every three weeks to release an immune brake. Researchers assess brain-tumor response or stability at eight weeks.
This phase 2 study plans 45 patients. Nancy Wang leads at Massachusetts General Hospital, Boston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.